| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Centre For Molecular Microbiology and Infection, Department of Biological Sciences, Imperial College London, London, United Kingdom; and
Chiron S.p.A., Siena, Italy
In a healthy individual, the lung contains few lymphoid cells. However, amplified immune responses, as exemplified during lung infection, can cause extensive tissue damage. We have previously demonstrated that one lung infection modulates the immunopathological outcome to a subsequent unrelated pathogen. Mimicking heterologous immunity may provide a means of enhancing both innate and acquired immunity. We now show that prior lung administration of a modified heat-labile toxin from Escherichia coli (LTK63) enhances immunity to respiratory syncytial virus, influenza virus, and the fungus Cryptococcus neoformans. Treatment with LTK63 decreased lung inflammation and tissue damage and improved the ability to resolve the infection. APCs expressing the activation markers MHC class II, CD80, and CD40 increased in number in the lung. LTK63 treatment increased the pathogen-specific IgA response in the nasal mucosa and simultaneously decreased inflammatory cytokine production (IFN-
and TNF-
) after infection. The number of activated CD8+CD44+ T cells and the respiratory syncytial virus- or influenza-specific CD8-proliferative responses increased, although the total inflammatory infiltrate was reduced. LTK63 treatment matured lung APCs (LTK63 prevented efficient presentation of whole OVA to DO11.10 cells, whereas OVA peptide presentation was unaffected), enhanced immunity in both a Th1 and Th2 environment, was long lasting, and was not pathogen or host strain specific; the protective effects were partially independent of T and B cells. Innate imprinting by toxin-based immunotherapeutics may provide generic protection against infectious disease in the lung, without the need for coadministered pathogen-specific Ag.
This article has been cited by other articles:
|
|
 |
|
  F. Zhou, A. Goodsell, Y. Uematsu, and M. Vajdy Prolonged Protection against Intranasal Challenge with Influenza Virus following Systemic Immunization or Combinations of Mucosal and Systemic Immunizations with a Heat-Labile Toxin Mutant Clin. Vaccine Immunol., April 1, 2009; 16(4): 471 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Clement, S. E. Evans, C. M. Evans, D. Hawke, R. Kobayashi, P. R. Reynolds, S. J. Moghaddam, B. L. Scott, E. Melicoff, R. Adachi, et al. Stimulation of Lung Innate Immunity Protects against Lethal Pneumococcal Pneumonia in Mice Am. J. Respir. Crit. Care Med., June 15, 2008; 177(12): 1322 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sabroe, L. C. Parker, S. K. Dower, and M. K. B. Whyte Practical and Conceptual Models of Chronic Obstructive Pulmonary Disease Proceedings of the ATS, December 1, 2007; 4(8): 606 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Goulding, R. Snelgrove, J. Saldana, A. Didierlaurent, M. Cavanagh, E. Gwyer, J. Wales, E. L. Wissinger, and T. Hussell Respiratory Infections: Do We Ever Recover? Proceedings of the ATS, December 1, 2007; 4(8): 618 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tritto, A. Muzzi, I. Pesce, E. Monaci, S. Nuti, G. Galli, A. Wack, R. Rappuoli, T. Hussell, and E. De Gregorio The Acquired Immune Response to the Mucosal Adjuvant LTK63 Imprints the Mouse Lung with a Protective Signature J. Immunol., October 15, 2007; 179(8): 5346 - 5357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Parez, C. Fourgeux, A. Mohamed, C. Dubuquoy, M. Pillot, A. Dehee, A. Charpilienne, D. Poncet, I. Schwartz-Cornil, and A. Garbarg-Chenon Rectal Immunization with Rotavirus Virus-Like Particles Induces Systemic and Mucosal Humoral Immune Responses and Protects Mice against Rotavirus Infection J. Virol., February 15, 2006; 80(4): 1752 - 1761. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
